{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:16:00Z","timestamp":1778156160953,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clbc.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:04:20Z","timestamp":1775181860000},"page":"91-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patterns of Disease Progression in Advanced Breast Cancer Patients Treated With Cyclin D Kinase 4\/6 Inhibitors: Prognostic and Therapeutic Implications"],"prefix":"10.1016","volume":"26","author":[{"given":"Sudhir","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1260-7710","authenticated-orcid":false,"given":"Rossanna C.","family":"Pezo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.clbc.2026.04.001_bib0001","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clbc.2026.04.001_bib0002","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"issue":"32","key":"10.1016\/j.clbc.2026.04.001_bib0003","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.001_bib0004","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.001_bib0005","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clbc.2026.04.001_bib0006","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.7150\/jca.18196","article-title":"Rapid breast cancer disease progression following cyclin dependent kinase 4 and 6 inhibitor discontinuation","volume":"8","author":"Bashour","year":"2017","journal-title":"J Cancer"},{"issue":"8","key":"10.1016\/j.clbc.2026.04.001_bib0007","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/oncolo\/oyad035","article-title":"Real-world evaluation of disease progression after CDK 4\/6 inhibitor therapy in patients with hormone receptor-positive metastatic breast cancer","volume":"28","author":"West","year":"2023","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.clbc.2026.04.001_bib0008","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1038\/onc.2016.379","article-title":"Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.001_bib0009","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.001_bib0010","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12282-020-01150-8","article-title":"Resistance to cyclin-dependent kinase (CDK) 4\/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells","volume":"28","author":"Ogata","year":"2021","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2026.04.001_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17588359231156387","article-title":"Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC","volume":"15","author":"Xuzhang","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.001_bib0012","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/s41598-021-81666-x","article-title":"Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients","volume":"11","author":"Heo","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterization and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organization for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.clbc.2026.04.001_bib0014","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.3390\/cancers14133262","article-title":"Tumor burden reporting in phase III clinical trials of metastatic lung, breast, and colorectal cancers: a systematic review","volume":"14","author":"Santorsola","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.001_bib0015","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1470-2045(22)00034-1","article-title":"Initial tumor burden and hidden oligometastatic disease in phase 3 clinical trials","volume":"23","author":"Ottaiano","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.001_bib0016","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-20-3337","article-title":"(Oligo)metastasis as a spectrum of disease","volume":"81","author":"Gutiontov","year":"2021","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.clbc.2026.04.001_bib0017","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.cell.2012.04.023","article-title":"The life history of 21 breast cancers","volume":"149","author":"Nik-Zainal","year":"2012","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.001_bib0018","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clbc.2026.04.001_bib0019","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s43018-021-00229-1","article-title":"Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment","volume":"2","author":"Pasha","year":"2021","journal-title":"Nat Cancer"},{"issue":"9","key":"10.1016\/j.clbc.2026.04.001_bib0020","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-16-2717","article-title":"Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer","volume":"77","author":"Cejalvo","year":"2017","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.001_bib0021","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11912-024-01529-2","article-title":"Navigating breast cancer oligometastasis and oligoprogression: current landscape and future directions","volume":"26","author":"Yoon","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.001_bib0022","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/annonc\/mds248","article-title":"Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis","volume":"24","author":"Dieci","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.001_bib0023","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41523-021-00252-6","article-title":"Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort","volume":"7","author":"Grinda","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.001_bib0024","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nbt.2576","article-title":"Identification of a population of blood circulating tumor cells from breast cancer patients who initiates metastasis in a xenograft assay","volume":"31","author":"Baccelli","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.001_bib0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","article-title":"Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients","volume":"185","author":"Nguyen","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.clbc.2026.04.001_bib0026","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1367159","article-title":"Patterns of progression in metastatic estrogen receptor positive breast cancer: an argument for local therapy","volume":"2017","author":"Kelly","year":"2017","journal-title":"Int J Breast Cancer"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.001_bib0027","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1111\/cas.14605","article-title":"Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer","volume":"111","author":"Kagawa","year":"2020","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.001_bib0028","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/cancers12041046","article-title":"Oligoprogressive non-small cell lung cancer under treatment with PD-(L)1 inhibitors","volume":"12","author":"Rheinheimer","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.clbc.2026.04.001_bib0029","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.3390\/ijms26073357","article-title":"Impact of patient profile on CDK4\/6 inhibitor therapy outcomes: a real-world data analysis","volume":"26","author":"Stanciu","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.001_bib0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-023-07226-1","article-title":"The association between HER2-low status and survival in patients with metastatic breast cancer treated with cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis","volume":"204","author":"Guven","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.04.001_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114906","article-title":"Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure","volume":"164","author":"Roncato","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"10.1016\/j.clbc.2026.04.001_bib0032","doi-asserted-by":"crossref","first-page":"327","DOI":"10.21037\/atm-23-965","article-title":"Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4\/6 inhibitors beyond progression","volume":"11","author":"Foldi","year":"2023","journal-title":"Ann Transl Med"},{"issue":"7","key":"10.1016\/j.clbc.2026.04.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00531","article-title":"Cyclin-dependent kinase 4\/6 inhibitors beyond progression in metastatic breast cancer: a retrospective real-world biomarker analysis","volume":"7","author":"Gerratana","year":"2023","journal-title":"JCO Precis Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:43:25Z","timestamp":1778154205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1526820926000534"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.001","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of Disease Progression in Advanced Breast Cancer Patients Treated With Cyclin D Kinase 4\/6 Inhibitors: Prognostic and Therapeutic Implications","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}